Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire
Keywords:
patient-reported outcome measure, dysgeusia, sonic hedgehog inhibitors, PROM, basal cell carcinomaAbstract
Introduction: Dysgeusia may occur during conventional or target-therapies and affect patients adherence-to-treatment. Therefore, it should be monitored to improve clinical outcome. To date, available questionnaires on dysgeusia relate to traditional antineoplastics and do not apply to target-therapies as the pathogenetic mechanism and clinical expression differ.
Objectives: To develop a patient-reported outcome measure (PROM) to screen for and monitor the occurrence and severity of dysgeusia in patients under Smoothened (SMO) inhibitors: the SMO-iD questionnaire.
Methods: Patients with locally advanced basal cell carcinomas referring dysgeusia under SMO inhibitors at the University Hospital of Naples Federico II, were enrolled between January-December 2020. The PROM was elaborated based on chemotherapy-induced dysgeusia (CiTas) scale (development phase) and then validated by measuring internal consistency and reliability (validation phase).
Results: Thirty-nine patients were enrolled and interviewed every 8 weeks. In the first phase, 160 CiTas questionnaires were collected, and the SMO-iD questionnaire was developed. In the second phase, 195 SMO-iD questionnaires were recorded, and reliability and validity assessed. Cronbach alpha was 0.89.
Conclusions: The SMO-iD questionnaire is a validated questionnaire that shows high face and content validity as well as high internal consistency and reliability. Hence, it may be introduced in daily clinical setting to monitor dysgeusia in patients under SMO-inhibitors.
References
Jafari A, Alaee A, Ghods K. The etiologies and considerations of dysgeusia: A review of literature. J Oral Biosci. 2021;63(4):319-326. DOI: 10.1016/j.job.2021.08.006. PMID: 34487857.
Malta CEN, de Lima Martins JO, Carlos ACAM, et al. Risk factors for dysgeusia during chemotherapy for solid tumors: a retrospective cross-sectional study. Support Care Cancer. 2022; 30(1):313-325. DOI: 10.1007/s00520-021-06219-4. PMID: 34283319.
Sözeri E, Kutlutürkan S. Taste Alteration in Patients Receiving Chemotherapy. Breast Health. 2015;11(2):81-87.DOI: 10.5152/tjbh.2015.2489. PMID: 28331697. PMCID: PMC5351492.
Kumari A, Ermilov AN, Allen BL, et al. Hedgehog pathway blockade with the cancer drug LDE225 disrupts taste organs and taste sensation. J Neurophysiol. 2015;113(3):1034-1040. DOI: 10.1152/jn.00822.2014. PMID: 25392175. PMCID: PMC4312875.
Hall JMH, Bell ML, Finger TE. Disruption of Sonic hedgehog signaling alters growth and patterning of lingual taste papillae. Dev Biol. 2003;255(2):263-277. DOI: 10.1016/s0012-1606(02)00048-9. PMID: 12648489.
Mokkink LB, Patrick DL, Alonso J, et al. COSMIN Study Design checklist for Patient-reported outcome measurement instruments. 2019. Available at: https://www.cosmin.nl/wp-content/uploads/COSMIN-study-designing-checklist_final.pdf.Accessed January 2022).
Kano T, Kanda K. Development and validation of a chemotherapy-induced taste alteration scale. Oncol Nurs Forum. 2013;40 (2):E79-85. DOI: 10.1188/13.ONF.E79-E85. PMID: 23448748.
Simeone S, Esposito MR, Gargiulo G, et al. The CiTAS scale for evaluating taste alteration induced by chemotherapy: state of the art on its clinical use. Acta Biomed. 2019;90:17–25. doi: 10.23750/abm.v90i6-S.8278. PMID: 31292411; PMCID: PMC6776177.
Erivedge, INN-Vismodegib - European Medicines Agency: Summary of Product Characteristics [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/erivedge-epar-product-information_en.pdf. Jan 2022.
Odomzo, INN-Sonidegib - European Medicines Agency: Summary of Product Characteristics [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/odomzo-epar-product-information_en.pdf. Jan 2022.
Alam A, Farooq U, Singh R, et al. Chemotherapy Treatment and Strategy Schemes : A Review Chemotherapy Treatment and Strategy Schemes : A Review. Open Acc J of Toxicol. 2018;2(5): 555600. DOI: 10.19080/OAJT.2018.02.555600.
Gutzmer R, Solomon JA. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma. Target Oncol. 2019;14(3):253-267. DOI: 10.1007/s11523-019-00648-2. PMID: 31243642.Target Oncol [Internet]. 2019;14:253–267. DOI:10.1007/s11523-019-00648-2.
Villani A, Costa C, Fabbrocini G, et al. Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: a retrospective case series. J Am Acad Dermatol. 2021;84(4):e211-e212. DOI: 10.1016/j.jaad.2020.12.006. PMID: 33301802. 14. Villani A, Megna M, Fabbrocini G, et al. Long-Term Efficacy of Vismodegib After its Withdrawal and Patients’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI). Dermatol Ther (Heidelb). 2019;9(4):719-724. DOI: 10.1007/s13555-019-00323-4. PMID: 31506916. PMCID: PMC6828856.9:719–724.
Published
Issue
Section
License
Copyright (c) 2023 Elisa Camela, Alessia Villani, Sonia Sofia Ocampo Garza, Claudia Costa, Gabriella Fabbrocini, Matteo Megna, Luca Potestio, Angelo Ruggiero, Massimiliano Scalvenzi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
